Plug Power And Rockwell Automation On The List Of Winners And Losers Of Wednesday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Plug Power, Gulf Coast Ultra Deep Royalty Trust, and Rumble.

Rank Financial Asset Price Change Updated (EST)
1 Plug Power (PLUG) 4.48 20.04% 2024-01-31 15:14:28
2 Gulf Coast Ultra Deep Royalty Trust (GULTU) 0.01 20% 2024-01-30 19:13:05
3 Rumble (RUM) 7.09 16.42% 2024-01-31 15:24:06
4 Gyrodyne (GYRO) 9.65 13.98% 2024-01-31 12:12:52
5 FibroGen (FGEN) 1.89 9.59% 2024-01-31 15:12:24
6 iShares FTSE EPRA/NAREIT Europe (IFEU) 35.08 7.21% 2024-01-31 03:09:05
7 RenaissanceRe Hold (RNR) 229.18 6.57% 2024-01-31 15:58:48
8 Edwards Lifesciences (EW) 78.51 6.24% 2024-01-31 15:55:04
9 Stryker Corp (SYK) 335.91 6.09% 2024-01-31 15:59:31
10 Inogen (INGN) 6.34 5.58% 2024-01-31 04:44:06

The three biggest losers today are Rockwell Automation, MarketAxess Holdings, and Teradyne.

Rank Financial Asset Price Change Updated (EST)
1 Rockwell Automation (ROK) 252.83 -17.7% 2024-01-31 15:58:50
2 MarketAxess Holdings (MKTX) 229.09 -16.49% 2024-01-31 15:13:51
3 Teradyne (TER) 96.98 -7.28% 2024-01-31 15:17:56
4 Alphabet (GOOGL) 141.20 -6.77% 2024-01-31 15:10:12
5 Pacific Biosciences of California (PACB) 6.57 -6.48% 2024-01-31 15:14:24
6 The Intergroup Corporation (INTG) 23.40 -6.4% 2024-01-31 05:08:05
7 Lakeland Financial Corporation (LKFN) 67.83 -5.53% 2024-01-31 15:08:06
8 Transocean (RIG) 5.47 -5.38% 2024-01-31 15:58:39
9 Boston Properties (BXP) 66.46 -5.06% 2024-01-31 15:53:38
10 Thermo Fisher Scientific (TMO) 538.86 -4.98% 2024-01-31 15:59:50

Winners today

1. Plug Power (PLUG) – 20.04%

Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power jumping 20.04% to $4.48 on Wednesday while NASDAQ fell 2.23% to $15,164.01.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.57%.

Volume

Today’s last reported volume for Plug Power is 110301000 which is 149.62% above its average volume of 44186200.

Sales Growth

Plug Power’s sales growth is 78.4% for the current quarter and 59% for the next.

More news about Plug Power.

2. Gulf Coast Ultra Deep Royalty Trust (GULTU) – 20%

Gulf Coast Ultra Deep Royalty Trust operates as a statutory trust. It holds a 5% gross overriding royalty interest in future production from the McMoRan Oil & Gas LLC inboard lower tertiary/cretaceous exploration prospects located in the shallow waters of the Gulf of Mexico and onshore in South Louisiana. The company was incorporated in 2012 and is based in Houston, Texas.

NASDAQ ended the session with Gulf Coast Ultra Deep Royalty Trust rising 20% to $0.01 on Wednesday while NASDAQ fell 2.23% to $15,164.01.

Earnings Per Share

As for profitability, Gulf Coast Ultra Deep Royalty Trust has a trailing twelve months EPS of $0.01.

PE Ratio

Gulf Coast Ultra Deep Royalty Trust has a trailing twelve months price to earnings ratio of 1.2. Meaning, the purchaser of the share is investing $1.2 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 263.38%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Gulf Coast Ultra Deep Royalty Trust’s EBITDA is -29.93.

Yearly Top and Bottom Value

Gulf Coast Ultra Deep Royalty Trust’s stock is valued at $0.01 at 16:32 EST, way below its 52-week high of $0.05 and way above its 52-week low of $0.00.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Apr 26, 2023, the estimated forward annual dividend rate is 0.01 and the estimated forward annual dividend yield is 59.55%.

Volume

Today’s last reported volume for Gulf Coast Ultra Deep Royalty Trust is 495825 which is 142.32% above its average volume of 204609.

More news about Gulf Coast Ultra Deep Royalty Trust.

3. Rumble (RUM) – 16.42%

Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.

NASDAQ ended the session with Rumble jumping 16.42% to $7.09 on Wednesday while NASDAQ dropped 2.23% to $15,164.01.

Earnings Per Share

As for profitability, Rumble has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.68%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Rumble’s EBITDA is -28.51.

Sales Growth

Rumble’s sales growth is 41% for the current quarter and 27.6% for the next.

More news about Rumble.

4. Gyrodyne (GYRO) – 13.98%

Gyrodyne, LLC owns and manages a diversified portfolio of real estate properties comprising office, industrial and service-oriented properties in the New York metropolitan area. Gyrodyne owns a 63 acre site approximately 50 miles east of New York City on the north shore of Long Island, which includes industrial and office buildings and undeveloped property which is the subject of plans to seek value-enhancing entitlements. Gyrodyne also owns a medical office park in Cortlandt Manor, New York which is also the subject of a subdivision application. Gyrodyne's common shares are traded on the NASDAQ Stock Market under the symbol GYRO.

NASDAQ ended the session with Gyrodyne rising 13.98% to $9.65 on Wednesday, after four sequential sessions in a row of losses. NASDAQ slid 2.23% to $15,164.01, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Gyrodyne has a trailing twelve months EPS of $0.21.

PE Ratio

Gyrodyne has a trailing twelve months price to earnings ratio of 45.97. Meaning, the purchaser of the share is investing $45.97 for every dollar of annual earnings.

Volatility

Gyrodyne’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.71%, a negative 0.53%, and a positive 2.84%.

Gyrodyne’s highest amplitude of average volatility was 5.71% (last week), 1.82% (last month), and 2.84% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 2.74M for the twelve trailing months.

More news about Gyrodyne.

5. FibroGen (FGEN) – 9.59%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen jumping 9.59% to $1.89 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 2.23% to $15,164.01, following the last session’s downward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

Revenue Growth

Year-on-year quarterly revenue growth grew by 155.1%, now sitting on 154.98M for the twelve trailing months.

Volume

Today’s last reported volume for FibroGen is 4486150 which is 95.64% above its average volume of 2293060.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen’s EBITDA is 1.67.

Sales Growth

FibroGen’s sales growth is 9.2% for the present quarter and 16.4% for the next.

More news about FibroGen.

6. iShares FTSE EPRA/NAREIT Europe (IFEU) – 7.21%

NASDAQ ended the session with iShares FTSE EPRA/NAREIT Europe rising 7.21% to $35.08 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ dropped 2.23% to $15,164.01, following the last session’s downward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, iShares FTSE EPRA/NAREIT Europe has a trailing twelve months EPS of $3.47.

More news about iShares FTSE EPRA/NAREIT Europe.

7. RenaissanceRe Hold (RNR) – 6.57%

RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance products in the United States and internationally. The company operates through Property, and Casualty and Specialty segments. The Property segment writes property catastrophe excess of loss reinsurance and excess of loss reinsurance to insure insurance and reinsurance companies against natural and man-made catastrophes, including hurricanes, earthquakes, typhoons, and tsunamis, as well as winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, such as proportional reinsurance, property per risk, property reinsurance, binding facilities, and regional U.S. multi-line reinsurance. The Casualty and Specialty segment writes various classes of products, such as directors and officers, medical malpractice, and professional indemnity; automobile and employer's liability, casualty clash, umbrella or excess casualty, workers' compensation, and general liability; financial and mortgage guaranty, political risk, surety, and trade credit; and accident and health, agriculture, aviation, cyber, energy, marine, satellite, and terrorism. The company distributes its products and services primarily through intermediaries. It also invests in and manages funds. RenaissanceRe Holdings Ltd. was founded in 1993 and is headquartered in Pembroke, Bermuda.

NYSE ended the session with RenaissanceRe Hold jumping 6.57% to $229.18 on Wednesday while NYSE dropped 1.01% to $16,917.49.

Earnings Per Share

As for profitability, RenaissanceRe Hold has a trailing twelve months EPS of $30.47.

PE Ratio

RenaissanceRe Hold has a trailing twelve months price to earnings ratio of 7.52. Meaning, the purchaser of the share is investing $7.52 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.84%.

Volume

Today’s last reported volume for RenaissanceRe Hold is 1293590 which is 173.08% above its average volume of 473695.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, RenaissanceRe Hold’s stock is considered to be oversold (<=20).

More news about RenaissanceRe Hold.

8. Edwards Lifesciences (EW) – 6.24%

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

NYSE ended the session with Edwards Lifesciences rising 6.24% to $78.51 on Wednesday, following the last session’s downward trend. NYSE fell 1.01% to $16,917.49, after four consecutive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Edwards Lifesciences has a trailing twelve months EPS of $2.34.

PE Ratio

Edwards Lifesciences has a trailing twelve months price to earnings ratio of 33.55. Meaning, the purchaser of the share is investing $33.55 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.06%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Edwards Lifesciences’s stock is considered to be oversold (<=20).

More news about Edwards Lifesciences.

9. Stryker Corp (SYK) – 6.09%

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

NYSE ended the session with Stryker Corp jumping 6.09% to $335.91 on Wednesday, after four successive sessions in a row of gains. NYSE slid 1.01% to $16,917.49, after four consecutive sessions in a row of gains, on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Stryker Corp has a trailing twelve months EPS of $8.26.

PE Ratio

Stryker Corp has a trailing twelve months price to earnings ratio of 40.67. Meaning, the purchaser of the share is investing $40.67 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.04%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Stryker Corp’s stock is considered to be oversold (<=20).

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 9% and 16.8%, respectively.

More news about Stryker Corp.

10. Inogen (INGN) – 5.58%

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; and related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

NASDAQ ended the session with Inogen rising 5.58% to $6.34 on Wednesday while NASDAQ fell 2.23% to $15,164.01.

Earnings Per Share

As for profitability, Inogen has a trailing twelve months EPS of $-5.76.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.58%.

More news about Inogen.

Losers Today

1. Rockwell Automation (ROK) – -17.7%

Rockwell Automation, Inc. provides industrial automation and digital transformation solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company operates through three segments, Intelligent Devices, Software & Control, and Lifecycle Services. Its solutions include hardware and software products and services. The Intelligent Devices segment offers drives, motion, safety, sensing, industrial components, and configured-to-order products. The Software & Control segment provides control and visualization software and hardware, information software, and network and security infrastructure solutions. The Lifecycle Services segment provides consulting, professional services and solutions, and connected and maintenance services. The company sells its solutions primarily through independent distributors in relation with its direct sales force. It serves discrete end markets, including automotive, semiconductor, and warehousing and logistics, as well as general industries comprising printing and publishing, marine, glass, fiber and textiles, airports, and aerospace; hybrid end markets, such as food and beverage, life sciences, household and personal care, and tire, as well as eco industrial, including water/wastewater, waste management, mass transit, and renewable energy; and process end markets comprising oil and gas, mining, metals, chemicals, pulp and paper, and others. Rockwell Automation, Inc. was founded in 1903 and is headquartered in Milwaukee, Wisconsin.

NYSE ended the session with Rockwell Automation falling 17.7% to $252.83 on Wednesday, after four successive sessions in a row of gains. NYSE fell 1.01% to $16,917.49, after four consecutive sessions in a row of gains, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Rockwell Automation has a trailing twelve months EPS of $11.95.

PE Ratio

Rockwell Automation has a trailing twelve months price to earnings ratio of 21.16. Meaning, the purchaser of the share is investing $21.16 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.81%.

Sales Growth

Rockwell Automation’s sales growth for the current quarter is 9%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Rockwell Automation’s stock is considered to be oversold (<=20).

Moving Average

Rockwell Automation’s value is way under its 50-day moving average of $288.02 and way under its 200-day moving average of $293.44.

Revenue Growth

Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 9.06B for the twelve trailing months.

More news about Rockwell Automation.

2. MarketAxess Holdings (MKTX) – -16.49%

MarketAxess Holdings Inc., together with its subsidiaries, operates an electronic trading platform for institutional investor and broker-dealer companies worldwide. It offers the access to liquidity in the U.S. investment-grade bonds, U.S. high-yield bonds, and U.S. Treasuries, as well as municipal bonds, emerging market debts, Eurobonds, and other fixed-income securities. The company, through its Open Trading protocols, executes bond trades between and among institutional investor and broker-dealer clients in an all-to-all anonymous trading environment for corporate bonds. It also offers trading-related products and services, including composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services to optimize trading environments. In addition, the company provides various pre-and post-trade services, such as trade matching, trade publication, regulatory transaction reporting, and market and reference data across a range of fixed-income and other products. MarketAxess Holdings Inc. was incorporated in 2000 and is headquartered in New York.

NASDAQ ended the session with MarketAxess Holdings falling 16.49% to $229.09 on Wednesday, following the last session’s downward trend. NASDAQ fell 2.23% to $15,164.01, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, MarketAxess Holdings has a trailing twelve months EPS of $6.58.

PE Ratio

MarketAxess Holdings has a trailing twelve months price to earnings ratio of 34.82. Meaning, the purchaser of the share is investing $34.82 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.42%.

Sales Growth

MarketAxess Holdings’s sales growth is 10.7% for the ongoing quarter and 8.6% for the next.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 9.5% and 0.5%, respectively.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Nov 6, 2023, the estimated forward annual dividend rate is 2.88 and the estimated forward annual dividend yield is 1.04%.

Moving Average

MarketAxess Holdings’s value is way below its 50-day moving average of $263.04 and way under its 200-day moving average of $258.85.

More news about MarketAxess Holdings.

3. Teradyne (TER) – -7.28%

Teradyne, Inc. designs, develops, manufactures, sells, and supports automatic test equipment worldwide. The company operates through Semiconductor Test, System Test, Industrial Automation, and Wireless Test segments. The Semiconductor Test segment offers products and services for wafer level and device package testing in automotive, industrial, communications, consumer, smartphones, cloud computer and electronic game, and other applications. This segment also provides FLEX test platform systems; J750 test system to address the volume semiconductor devices; Magnum platform that tests memory devices, such as flash memory and DRAM; and ETS platform for semiconductor manufacturers, and assembly and test subcontractors in the analog/mixed signal markets. It serves integrated device manufacturers that integrate the fabrication of silicon wafers into their business; fabless companies that outsource the manufacturing of silicon wafers; foundries; and semiconductor assembly and test providers. The System Test segment offers defense/aerospace test instrumentation and systems; storage test systems; and circuit-board test and inspection systems. The Industrial Automation segment provides collaborative robotic arms, autonomous mobile robots, and advanced robotic control software for manufacturing, logistics, and light industrial customers. The Wireless Test segment provides test solutions for use in the development and manufacture of wireless devices and modules, smartphones, tablets, notebooks, laptops, peripherals, and Internet-of-Things devices under the LitePoint brand name. This segment also offers IQxel products for Wi-Fi and other standards; IQxstream solution for testing GSM, EDGE, CDMA2000, TD-SCDMA, WCDMA, HSPA+, LTE, and 5G technologies; IQcell, a multi-device cellular signaling test solution; IQgig test solution; and turnkey test software for wireless chipsets. Teradyne, Inc. was incorporated in 1960 and is headquartered in North Reading, Massachusetts.

NASDAQ ended the session with Teradyne dropping 7.28% to $96.98 on Wednesday while NASDAQ fell 2.23% to $15,164.01.

Earnings Per Share

As for profitability, Teradyne has a trailing twelve months EPS of $2.15.

PE Ratio

Teradyne has a trailing twelve months price to earnings ratio of 45.11. Meaning, the purchaser of the share is investing $45.11 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.47%.

Moving Average

Teradyne’s worth is under its 50-day moving average of $100.68 and under its 200-day moving average of $100.63.

Volume

Today’s last reported volume for Teradyne is 4815720 which is 189.71% above its average volume of 1662250.

Yearly Top and Bottom Value

Teradyne’s stock is valued at $96.98 at 16:32 EST, way under its 52-week high of $119.20 and way above its 52-week low of $81.08.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Teradyne’s stock is considered to be overbought (>=80).

More news about Teradyne.

4. Alphabet (GOOGL) – -6.77%

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, hardware, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play store; and Fitbit wearable devices, Google Nest home products, Pixel phones, and other devices, as well as in the provision of YouTube non-advertising services. The Google Cloud segment offers infrastructure, cybersecurity, data, analytics, AI, and machine learning, and other services; Google Workspace that include cloud-based collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells health technology and internet services. The company was founded in 1998 and is headquartered in Mountain View, California.

NASDAQ ended the session with Alphabet dropping 6.77% to $141.20 on Wednesday while NASDAQ fell 2.23% to $15,164.01.

Microsoft and Alphabet set to slide despite solid beats on revenues and profitsOver the year Alphabet said it also incurred $2.1bn in charges related to severance charges., With the share prices of Microsoft and Alphabet both getting January off to a strong start and Microsoft establishing itself as the biggest company in the world, overtaking Apple in the process as $3trn company the expectations management goes into overdrive.

Earnings Per Share

As for profitability, Alphabet has a trailing twelve months EPS of $5.8.

PE Ratio

Alphabet has a trailing twelve months price to earnings ratio of 24.34. Meaning, the purchaser of the share is investing $24.34 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.33%.

Moving Average

Alphabet’s value is above its 50-day moving average of $138.34 and above its 200-day moving average of $128.46.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11%, now sitting on 297.13B for the twelve trailing months.

More news about Alphabet.

5. Pacific Biosciences of California (PACB) – -6.48%

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

NASDAQ ended the session with Pacific Biosciences of California falling 6.48% to $6.57 on Wednesday, following the last session’s downward trend. NASDAQ dropped 2.23% to $15,164.01, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-1.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.46%.

Volatility

Pacific Biosciences of California’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.09%, a negative 1.64%, and a positive 4.29%.

Pacific Biosciences of California’s highest amplitude of average volatility was 2.85% (last week), 4.75% (last month), and 4.29% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Pacific Biosciences of California’s stock is considered to be oversold (<=20).

Sales Growth

Pacific Biosciences of California’s sales growth is 107.2% for the present quarter and 57% for the next.

More news about Pacific Biosciences of California.

6. The Intergroup Corporation (INTG) – -6.4%

The InterGroup Corporation, through its subsidiaries, operates a hotel under the Hilton San Francisco Financial District name located in San Francisco, California. The company operates through three segments: Hotel Operations, Real Estate Operations, and Investment Transactions. Its hotel consists of guest rooms and luxury suites, a restaurant, a lounge, a private dining room, meeting room space, a gym, a grand ballroom, 5-level underground parking garage, a pedestrian bridge, and a Chinese culture center. The company also invests in income-producing instruments, corporate debt and equity securities, publicly traded investment funds, mortgage-backed securities, securities issued by REITs, and other companies that invest primarily in real estate. In addition, it owns, manages, and invests in apartment complexes, single-family houses as strategic investments, and commercial real estate property located in the United States, as well as owns unimproved land in Maui, Hawaii. The InterGroup Corporation was founded in 1965 and is based in Los Angeles, California.

NASDAQ ended the session with The Intergroup Corporation falling 6.4% to $23.40 on Wednesday while NASDAQ slid 2.23% to $15,164.01.

Earnings Per Share

As for profitability, The Intergroup Corporation has a trailing twelve months EPS of $-4.57.

Moving Average

The Intergroup Corporation’s value is higher than its 50-day moving average of $21.74 and way below its 200-day moving average of $31.07.

Yearly Top and Bottom Value

The Intergroup Corporation’s stock is valued at $23.40 at 16:32 EST, way under its 52-week high of $47.89 and way above its 52-week low of $16.27.

Volume

Today’s last reported volume for The Intergroup Corporation is 1679 which is 35.32% below its average volume of 2596.

More news about The Intergroup Corporation.

7. Lakeland Financial Corporation (LKFN) – -5.53%

Lakeland Financial Corporation operates as the bank holding company for Lake City Bank that provides various banking products and services in the United States. The company accepts various deposit products, such as noninterest bearing, interest-bearing checking, savings, money market, NOW, and demand deposits. Its loan products include commercial and industrial, commercial real estate and multi-family residential, construction, agri-business and agricultural, consumer 1-4 family mortgage, and other consumer loans. The company also offers retail and merchant credit card services; corporate treasury management, wealth advisory, and trust services; retail brokerage services, including various financial and investment products, such as annuities and life insurance; and mobile business banking and on-line treasury management services. It serves commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and health care industries. The company was founded in 1872 and is headquartered in Warsaw, Indiana.

NASDAQ ended the session with Lakeland Financial Corporation sliding 5.53% to $67.83 on Wednesday while NASDAQ slid 2.23% to $15,164.01.

Earnings Per Share

As for profitability, Lakeland Financial Corporation has a trailing twelve months EPS of $3.65.

PE Ratio

Lakeland Financial Corporation has a trailing twelve months price to earnings ratio of 18.58. Meaning, the purchaser of the share is investing $18.58 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.39%.

Volume

Today’s last reported volume for Lakeland Financial Corporation is 90745 which is 18.94% below its average volume of 111960.

More news about Lakeland Financial Corporation.

8. Transocean (RIG) – -5.38%

Transocean Ltd., together with its subsidiaries, provides offshore contract drilling services for oil and gas wells worldwide. It contracts its mobile offshore drilling rigs, related equipment, and work crews to drill oil and gas wells. It serves integrated energy companies, government-owned or government-controlled energy companies, and other independent energy companies. Transocean Ltd. was founded in 1926 and is based in Steinhausen, Switzerland.

NYSE ended the session with Transocean dropping 5.38% to $5.47 on Wednesday, after four successive sessions in a row of gains. NYSE dropped 1.01% to $16,917.49, after four consecutive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Transocean has a trailing twelve months EPS of $-1.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.14%.

Volume

Today’s last reported volume for Transocean is 25229100 which is 60.38% above its average volume of 15730300.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.2%, now sitting on 2.7B for the twelve trailing months.

Previous days news about Transocean

  • Why transocean (rig) outpaced the stock market today. According to Zacks on Monday, 29 January, "In the latest market close, Transocean (RIG Quick QuoteRIG – Free Report) reached $5.77, with a +1.05% movement compared to the previous day. ", "Looking at valuation, Transocean is presently trading at a Forward P/E ratio of 35.06. "

More news about Transocean.

9. Boston Properties (BXP) – -5.06%

BXP (NYSE: BXP) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets – Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by unconsolidated joint ventures, BXP's portfolio totals 53.5 million square feet and 190 properties, including 11 properties under construction/redevelopment.

NYSE ended the session with Boston Properties sliding 5.06% to $66.46 on Wednesday while NYSE slid 1.01% to $16,917.49.

Earnings Per Share

As for profitability, Boston Properties has a trailing twelve months EPS of $1.23.

PE Ratio

Boston Properties has a trailing twelve months price to earnings ratio of 54.03. Meaning, the purchaser of the share is investing $54.03 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.58%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Boston Properties’s EBITDA is 93.79.

Volume

Today’s last reported volume for Boston Properties is 2137020 which is 30.59% above its average volume of 1636320.

More news about Boston Properties.

10. Thermo Fisher Scientific (TMO) – -4.98%

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

NYSE ended the session with Thermo Fisher Scientific sliding 4.98% to $538.86 on Wednesday, after five sequential sessions in a row of gains. NYSE slid 1.01% to $16,917.49, after four sequential sessions in a row of gains, on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Thermo Fisher Scientific has a trailing twelve months EPS of $15.26.

PE Ratio

Thermo Fisher Scientific has a trailing twelve months price to earnings ratio of 35.31. Meaning, the purchaser of the share is investing $35.31 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.28%.

Moving Average

Thermo Fisher Scientific’s value is higher than its 50-day moving average of $506.18 and higher than its 200-day moving average of $519.94.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1%, now sitting on 43.42B for the twelve trailing months.

Sales Growth

Thermo Fisher Scientific’s sales growth is negative 6.3% for the ongoing quarter and negative 3.6% for the next.

More news about Thermo Fisher Scientific.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *